Epidermolysis bullosa acquisita is a rare autoimmune subepidermal blistering disease, often resisting current treatments, especially systemic corticosteroids. We report a patient having a bullous pemphigoid who relapsed with clinical and immunological features of inflammatory epidermolysis bullosa acquisita. An anti-CD20 monoclonal antibody (rituximab) was proposed because of resistance to high-dose steroids and other immunosuppressive agents. The disease dramatically improved within a few weeks following rituximab infusion allowing the decrease in steroid therapy. Our case illustrates also the possible evolution from bullous pemphigoid to epidermolysis bullosa acquisita that should be suspected when clinical atypia occurs or in case of corticosteroid resistance.

Joly P, Corville P, Lok C, et al: Clinical criteria for the diagnosis of bullous pemphigoid: a reevaluation according to immunoblot analysis of patient sera. Dermatology 2004;208:16–20.
Woodley DT, Sarret Y, Briggaman RA: Autoimmunity to type VII collagen. Semin Dermatol 1991;10:232–239.
Schmidt E, Hunzelmann N, Zillikens D, et al: Rituximab in refractory autoimmune bullous diseases. Clin Exp Dermatol 2006;31:503–508.
Batteux F, Franck N, Jaffray P, et al: An extract from cultured human keratinocytes that contains the major autoantigens related to autoimmune bullous skin diseases. J Clin Immunol 1997;17:228–233.
König A, Raghunath M, Steimann B, Bruckner-Tuderman L: Intracellular accumulation of collagen VII in cultured keratinocytes from patient with dominant dystrophic epidermolysis bullosa. J Invest Dermatol 1994;102:105–110.
Engineer L, Razzaque Ahmed A: Emerging treatment for epidermolysis bullosa acquisita. J Am Acad Dermatol 2001;44:818–828.
Heizmann M, Itin P, Wernli M, et al: Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am J Hematol 2001;66:142–144.
Borradori L, Lombardi T, Samson J, et al: Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20+ follicular lymphoma-associated paraneoplastic pemphigus. Arch Dermatol 2001;137:269–272.
Arin MJ, Engert A, Krieg T, Hunzelmann N: Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol 2005;153:620–625.
Johnson PW, Glennie MJ: Rituximab: mechanisms and applications. Br J Cancer 2001;85:1619–1623.
Perosa F, Favoino E, Caragnano MA, et al: CD20: a target antigen for immunotherapy of autoimmune diseases. Autoimmun Rev 2005;4:526–531.
Edwards JC, Szczepanski L, Szechinski J, et al: Efficacy of B-cell targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572–2581.
Leyendeckers H, Tasanen K, Bruckner-Tudermann L, et al: Memory B cells specific for the NC16A domain of the 180 kDa bullous pemphigoid autoantigen can be detected in peripheral blood of bullous pemphigoid patients and induced in vitro to synthesize autoantibodies. J Invest Dermatol 2003;120:372–378.
Hertl M, Eming R, Veldman C: T cell control in autoimmune bullous skin disorders. J Clin Invest 2006;116:1159–1166.
Schmidt E, Benoit S, Brocker EB, et al: Successful adjuvant treatment of recalcitrant epidermolysis bullosa acquisita with anti-CD20 antibody rituximab. Arch Dermatol 2006;142:147–150.
Osawa M, Demitsu T, Toda S, et al: A case of mixed bullous disease of epidermolysis bullosa acquisita and linear IgA bullous dermatosis. Dermatology 2005;211:146–148.
Yamada T, Suzuki M, Koike Y, et al: A case of epidermolysis bullosa acquisita with autoantibody to anti-p200 pemphigoid antigen and exfoliative esophagitis. Dermatology 2006;212:381–384.
Kawachi Y, Ikegami M, Hashimoto T, et al: Autoantibodies to bullous pemphigoid and epidermolysis bullosa acquisita antigens in an infant. Br J Dermatol 1996;135:443–447.
Fairley JA, Woodley DT, Chen M, et al: A patient with both bullous pemphigoid and epidermolysis bullosa acquisita: an example of intermolecular epitope spreading. J Am Acad Dermatol 2004;51:118–122.
Chan LS, Vanderlugt CJ, Hashimoto T, et al: Epitope spreading: lessons from autoimmune skin diseases. J Invest Dermatol 1998;110:103–109.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.